Showing results (31-40 of 46) with videos related to
Sort By:
Pageof 5
Breast Cancer Research : BCR|November 16, 2019
Actionability of HER2-amplified circulating tumor cells in HER2-negative metastatic breast cancer: the CirCe T-DM1 trialWilliam Jacot, Paul Cottu, Frederique Berger, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 6, 2023
Overall Survival With Circulating Tumor Cell Count-Driven Choice of Therapy in Advanced Breast Cancer: A Randomized TrialFrançois-Clément Bidard, Nicolas Kiavue, William Jacot, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 18, 2009
Trastuzumab for patients with axillary-node-positive breast cancer: results of the FNCLCC-PACS 04 trialMarc Spielmann, Henri Roché, Thierry Delozier, et al.Clinical Breast Cancer|November 26, 2013
Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2Kathleen I Pritchard, Howard A Burris, Yoshinori Ito, et al.Breast (Edinburgh, Scotland)|February 20, 2024
Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast studyGilles Freyer, Noelia Martinez-Jañez, Bożena Kukielka-Budny, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 6, 2021
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast CancerBora Lim, David A Potter, Mohamad A Salkeni, et al.European Journal of Cancer (Oxford, England : 1990)|June 19, 2017
Superimposable outcomes for sequential and concomitant administration of adjuvant trastuzumab in HER2-positive breast cancer: Results from the SIGNAL/PHARE prospective cohortXavier Pivot, Pierre Fumoleau, Jean-Yves Pierga, et al.JAMA Oncology|November 5, 2020
Efficacy of Circulating Tumor Cell Count-Driven vs Clinician-Driven First-line Therapy Choice in Hormone Receptor-Positive, ERBB2-Negative Metastatic Breast Cancer: The STIC CTC Randomized Clinical TrialFrançois-Clément Bidard, William Jacot, Nicolas Kiavue, et al.Journal of the National Cancer Institute|August 3, 2006
Randomized phase III trial of topotecan following carboplatin and paclitaxel in first-line treatment of advanced ovarian cancer: a gynecologic cancer intergroup trial of the AGO-OVAR and GINECOJacobus Pfisterer, Béatrice Weber, Alexander Reuss, et al.Gynecologic Oncology|July 28, 2022
Paclitaxel with or without pazopanib for ovarian cancer relapsing during bevacizumab maintenance therapy: The GINECO randomized phase II TAPAZ studyFlorence Joly, Michel Fabbro, Dominique Berton, et al.Pageof 5